Early Use of Liver Histotripsy Treatment Tracked in New Study

Three years after the U.S. Food and Drug Administration (FDA) approved the HistoSonics Edison histotripsy system for treating liver tumors, researchers are now analyzing how widely the technology has been adopted in clinical settings.

A team at the University of Virginia, led by Dr. Allan Tsung, chair of the Department of Surgery, conducted an initial assessment to track the system’s early use across the United States.

The study aims to provide insights into how often the technology is being used and for which types of liver tumors, including both primary and metastatic cases.

Based on reporting from Medical Xpress (Cancer).

Source: Medical Xpress (Cancer). This article was drafted by AI from that reporting and reviewed by an automated accuracy check before publishing.